Retrospective Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 28, 2017; 9(36): 1352-1360
Published online Dec 28, 2017. doi: 10.4254/wjh.v9.i36.1352
Impact of sustained virologic response on chronic kidney disease progression in hepatitis C
Elizabeth S Aby, Tien S Dong, Jenna Kawamoto, Joseph R Pisegna, Jihane N Benhammou
Elizabeth S Aby, Tien S Dong, Jenna Kawamoto, Joseph R Pisegna, Jihane N Benhammou, Division of Gastroenterology, Hepatology and Parenteral Nutrition, Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, United States
Elizabeth S Aby, Tien S Dong, Joseph R Pisegna, Jihane N Benhammou, the Vatche and Tamar Manoukian Division of Digestive Diseases, UCLA Los Angeles, Department of Medicine, University of California David Geffen School of Medicine, Los Angeles, CA 90095, United States
Author contributions: Aby ES, Dong TS, Kawamoto J, Pisegna JR and Benhammou JN were involved in study concept and design; Aby ES and Dong TS were involved in data acquisition; Aby ES, Dong TS and Benhammou JN were involved in analysis and interpretation of data; Aby ES drafted the manuscript; Dong TS, Pisegna JR and Benhammou JN were involved in critical revision of the manuscript for important intellectual content; Dong TS performed the statistical analysis; Pisegna JR provided administrative, technical and material support as well as study supervision.
Supported by Department of Veterans Affairs RR and D Merit Review, No. I01 RX000194 (to Pisegna JR); Human Studies CORE through CURE: Digestive Diseases Research Center supported by NIH grant; Nos. P30DK41301 (to Pisegna JR) and NIH T32 DK07180-43 (to Benhammou JN).
Institutional review board statement: This study was approved by the VA Institutional Review Board and the Research and Development Committee at VA Greater Los Angeles Health System (VAGLAHS). Tracking Number 2016-100938.
Informed consent statement: Due to the retrospective nature of this study, an exempt for informed consent was approved by the VA institutional review board.
Conflict-of-interest statement: The authors have no conflicts of interest to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jihane N Benhammou, MD, the Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, 11301 Wilshire Blvd., Los Angeles, CA 90073, United States. jbenhammou@mednet.ucla.edu
Telephone: +1-310-2683131 Fax: +1-310-2684096
Received: October 6, 2017
Peer-review started: October 6, 2017
First decision: November 7, 2017
Revised: November 17, 2017
Accepted: December 5, 2017
Article in press: December 6, 2017
Published online: December 28, 2017
Processing time: 82 Days and 6.3 Hours
Core Tip

Core tip: In hepatitis C patients treated with direct acting antivirals, there is a lesser decline in renal function in those who are treated and achieved sustained virological response at 12 wk (SVR12) compared to those who do not achieve SVR12. However, the decline in renal function is no different between those who achieve SVR12 and those who are never treated. This suggests that viral eradication may not be associated improvement in the progression of renal disease and other factors, such as cryoglobulinemia, may be implicated in renal disease progression.